Adalvo and Gedeon Richter announced on 10 August 2026 an expanded global partnership to co-develop and supply tirzepatide-based therapies, extending an existing collaboration around semaglutide. Tirzepatide, the dual GIP/GLP-1 receptor agonist behind Eli Lilly's Mounjaro and Zepbound, anchors the…
Adalvo and Gedeon Richter announced on 10 August 2026 that they are expanding their global partnership to co-develop and supply tirzepatide-based therapies. Tirzepatide is the active ingredient in Eli Lilly's Mounjaro and Zepbound, the dual GIP/GLP-1 receptor agonist used in type 2 diabetes and obesity. The agreement extends a collaboration between the two companies that was previously centered on Novo Nordisk's Wegovy, the semaglutide product, placing the pair on both major incretin franchises at once.
The companies characterized the therapeutic area as one of the most significant and fastest-growing areas in healthcare. The clinical record supports the claim. Tirzepatide and semaglutide are peptide-based medicines central to type 2 diabetes and obesity treatment, and both have generated registered trial programs that reach well beyond metabolism.
The announcement itself is short on detail. The accessible text is truncated behind a registration wall, so full details about the partnership's scope, terms, and markets were not available. The available text includes no financial terms, clinical data, dosing details, or regulatory filings. What is clear is the strategic direction: a partnership built around one incretin peptide is now committed to a second, and to the co-development and supply capacity that commitment requires.
The operative word in the announcement is expanded. Adalvo and Gedeon Richter already collaborated around semaglutide, the active ingredient of Wegovy. The new agreement extends that strategic collaboration into tirzepatide and into the two indications the molecule defines: type 2 diabetes and obesity.
In pharmaceutical practice, a co-development and supply agreement assigns specific work. One or both parties develop the product and its formulation; the supply side covers manufacturing and the distribution chain that moves the therapy to market. That division of labor is exactly what the two companies have now committed to twice, first for semaglutide and now for tirzepatide.
The agreement should not be mistaken for a clinical or regulatory event. No approved tirzepatide product from this partnership appears in the announcement, and no clinical data or filings are cited. It is a commercial commitment, and it is best assessed as one. It also signals growing industrial and competitive interest in peptide therapeutics beyond the innovator products. Mounjaro and Zepbound are Eli Lilly products; Wegovy is a Novo Nordisk product. Two other companies entering the tirzepatide supply space with their own co-development program is a statement about the expected size and durability of the incretin market.
Both molecules work through the incretin system, the hormonal response that primes insulin secretion after meals. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide GIP receptor and the glucagon-like peptide-1 GLP-1 receptor, the design the trial record calls combined GLP-1/GIP dual agonist therapy.
GLP-1 receptor activation potentiates glucose-stimulated insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite through central pathways. GIP, which also potentiates insulin secretion, was long treated as the lesser incretin. Tirzepatide's clinical profile, including weight loss that exceeds what GLP-1 agonism alone typically achieves, has made the contribution of GIP receptor activation one of the most active mechanistic questions in metabolic pharmacology, and it is the biological rationale for the molecule's commercial position.
Both drugs are engineered peptides. Native incretin hormones are degraded within minutes, which makes them useless as chronic outpatient therapies. The marketed molecules are modified to resist enzymatic breakdown and remain active long enough for practical dosing, and they are manufactured through peptide synthesis, purification, and aseptic fill-finish rather than conventional small-molecule tableting. That manufacturing reality is the reason supply agreements of this kind exist, and why the capacity behind them becomes a commercial asset in its own right.
One recent case report in the literature describes starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use in a non-obese, non-diabetic woman PMID 42381258 . The report is a narrow caution, but it is relevant to any expansion of access to this class: potent metabolic peptides distributed through new commercial channels still require medical oversight.
Peptide Atlas registry data on tirzepatide cover 251 registered clinical trials. The populated phase fields record Phase 2: 5, Phase 4: 2, Phase 3: 1, with 10 trials listed as recruiting. Most trials in the file carry no phase assignment in the dataset, which reflects the structure of registry records rather than the science. The recruiting trials illustrate where the molecule is heading:
Semaglutide's file is larger: 668 registered clinical trials, with a populated phase breakdown of Phase 2: 4, Phase 4: 4, Phase 3: 1, and 10 trials recruiting. Its named trials point in the same direction of expansion. NCT07430332 is a Phase 2 trial of a GLP-1 receptor agonist in stage 1 type 1 diabetes. NCT07614412 tests GLP-1 agonism for beta-cell preservation in recent-onset type 1 diabetes. NCT07462663 is a Phase 4 pilot of pre-surgical optimization in patients with obesity and early-stage endometrial cancer. NCT07586150 studies personalized pharmaco-lifestyle interventions in severe mental illness. NCT06977438 is a Phase 4 trial of a GLP-1 plus lifestyle program in childhood obesity. NCT07027969, the metabolic surgery trial, appears in both files.
Indexed PubMed literature on file stands at 188 papers for tirzepatide and 197 for semaglutide. Recent tirzepatide work includes a multicenter real-world comparison against semaglutide for obesity PMID 42383938 , improved metabolic outcomes in type 1 diabetes with overweight or obesity PMID 42387290 , a propensity-matched comparison against SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease PMID 42397506 , and a review of tirzepatide as a multi-organ integrator in metabolic disease PMID 42387035 . The semaglutide file includes a randomized trial on effort-based decision-making in major depressive disorder PMID 42054055 and a scoping review of retinal vascular events PMID 42348481 , both signs of the same movement beyond metabolism.
The third-party laboratory purity tests on file are a separate data point: 4 tests for tirzepatide with a highest observed purity of 99.864%, and 8 tests for semaglutide with a highest observed purity of 99.979%. For a class this commercially charged, independent verification of what is actually in the vial is not an administrative detail.
The first implication is manufacturing capacity. Peptide production is a specialized discipline: synthesis at scale, chromatographic purification, analytical characterization, and aseptic fill-finish for injectable products. A co-development and supply agreement distributes that workload across two organizations and commits production lines to incretin peptides over a long horizon. The purity results tracked by Peptide Atlas indicate the quality standard contract and co-development manufacturing is expected to meet.
The second implication is market access. A second commercial source of tirzepatide-based therapies gives payers, health systems, and patients an alternative to the innovator supply chain. That changes price negotiation, continuity of supply, and availability in markets where the originator products are delayed or unaffordable. The companies describe the partnership as global, and the geographic scope matters precisely because incretin demand is large enough that more than one manufacturing network can be sustained.
For clinicians, the practical effect is the arrival of more than one supplier for a medicine class used by millions of patients, which puts a premium on pharmacovigilance and on knowing exactly which product a patient receives. For researchers, a more crowded supplier market makes independent identity and purity testing more consequential, not less. For the supply chain, the announcement is a signal that peptide manufacturing capacity, not molecule discovery, is becoming the binding constraint in this therapeutic area.
The truncated announcement leaves the strategic picture incomplete. No financial terms have been disclosed. No licensing structure has been described. No regulatory filings are mentioned. Those omissions are not unusual for a partnership announcement, but they limit what can be concluded from it.
The open questions are specific. Which tirzepatide-based products, formulations, or indications does the partnership cover? What are the respective roles of Adalvo and Gedeon Richter in co-development and in supply? Which geographic markets does the global partnership actually include? Did the earlier semaglutide-based partnership produce regulatory approvals or launches that would inform expectations for this one? And have any financial or licensing terms been disclosed?
Each question has a concrete answer that would sharpen the picture: the full text of the announcement, subsequent regulatory filings, and observable commercial milestones such as marketing authorizations or product launches. The earlier semaglutide collaboration is the most useful benchmark available, precisely because it is the template this agreement extends. Until those details emerge, the right reading of the deal is a commercial bet on the durability of the incretin market, placed by two companies that now intend to compete in it with both leading peptide franchises.
Peptides referenced: Semaglutide, Tirzepatide, Glucagon, GLP-1.
Related reading: Tirzepatide tied to 32% lower MACE risk in real-world diabetes cohort, Meta-Analyses Question Long-Term Value of GLP-1 Weight-Loss Drugs, Lilly Lifts 2026 Guidance as Tirzepatide Sales Surge, Peptide Rivals Split, MHRA Yellow Card data link GLP-1 drugs to 153 fatality reports.